Gennex Laboratories Intrinsic Value
Gennex Laboratories intrinsic value. Gennex Laboratories (GENNEX) median intrinsic value is ₹17.74 from 9 valuation models (range ₹4–₹27), vs current price ₹8.87 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Analyse GENNEX institutional holdings to track promoter, FII and institutional holdings.
GENNEX Valuation Methods Summary — DCF, Graham Number & P/E
Gennex Laboratories intrinsic value across 9 models vs current price ₹8.87 — upside/downside and value range per method. For current market price and key ratios, visit Gennex Laboratories share price chart.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹14.96 | ₹11.97 - ₹17.95 | +68.7% | EPS: ₹0.68, Sector P/E: 22x |
| Book Value Method | asset | ₹22.17 | ₹19.95 - ₹24.39 | +149.9% | Book Value/Share: ₹97.08, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹17.74 | ₹15.97 - ₹19.51 | +100.0% | Revenue/Share: ₹73.33, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹17.74 | ₹15.97 - ₹19.51 | +100.0% | EBITDA: ₹28.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹22.17 | ₹17.74 - ₹26.60 | +149.9% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹4.35 | ₹3.91 - ₹4.79 | -51.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹10.51 | ₹9.46 - ₹11.56 | +18.5% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹17.74 | ₹15.97 - ₹19.51 | +100.0% | ROE: 8.6%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹26.61 | ₹23.95 - ₹29.27 | +200.0% | EPS: ₹0.68, BVPS: ₹97.08 |
GENNEX Intrinsic Value vs Market Price — All Valuation Models
Gennex Laboratories fair value range ₹4–₹27 vs current market price ₹8.87 across 9 valuation models. Browse GENNEX income statement for revenue, profit, balance sheet and cash flow data.
GENNEX Intrinsic Value Analysis — Undervalued or Overvalued?
Gennex Laboratories median intrinsic value ₹17.74, current price ₹8.87 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of GENNEX?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Gennex Laboratories (GENNEX) is ₹17.74 (median value). With the current market price of ₹8.87, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹4.35 to ₹26.61, indicating ₹4.35 - ₹26.61.
Is GENNEX undervalued or overvalued?
Based on our multi-method analysis, Gennex Laboratories (GENNEX) appears to be trading below calculated value by approximately 100.0%.
GENNEX Financial Health — Key Ratios vs Industry Benchmarks
Gennex Laboratories financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 8.6% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 13.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.50x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
GENNEX Cash Flow Quality — Operating & Free Cash Flow
Gennex Laboratories operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹-64 Cr | ₹-67 Cr | Negative Cash Flow | 3/10 |
| March 2025 | ₹-10 Cr | ₹-10 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-47 Cr | ₹-47 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹24 Cr | ₹5 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹12 Cr | ₹11 Cr | Positive Free Cash Flow | 8/10 |